Navigation Links
La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial

LJPC. More information about the Company is available on its Web site: http://www.ljpc.com.

The forward-looking statements in this press release involve significant risks and uncertainties, and a number of factors, both foreseen and unforeseen, could cause actual results to differ materially from our current expectations. Forward-looking statements include those that express a plan, belief, expectation, estimation, anticipation, intent, contingency, future development or similar expression. The analyses of clinical results of Riquent, previously known as LJP 394, our drug candidate for the treatment of systemic lupus erythematosus ("lupus"), and any other drug candidate that we may develop, including the results of any trials or models that are ongoing or that we may initiate in the future, could result in a finding that these drug candidates are not effective in large patient populations, do not provide a meaningful clinical benefit, or may reveal a potential safety issue requiring us to develop new candidates. The analysis of the data from our previous Phase 3 trial of Riquent showed that the trial did not reach statistical significance with respect to its primary endpoint, time to renal flare, or with respect to its secondary endpoint, time to treatment with high-dose corticosteroids or cyclophosphamide. The results from our clinical trials of Riquent, including the results of any trials that are ongoing or that we may initiate in the future, may not ultimately be sufficient to obtain regulatory clearance to market Riquent either in the United States or any other country, and we may be required to conduct additional clinical studies to demonstrate the safety and efficacy of Riquent in order to obtain marketing approval. There can be no assurance, however, that we will have the necessary resources to complete any current or future trials or that any such trials will sufficiently demonstrate the safety and
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:5/6/2015)... 6, 2015  Integrative medicine interventions lead to ... for chronic pain, depression, and stress, according to ... The Bravewell Collaborative . The findings are based ... Medicine Interventions Effectiveness Registry (PRIMIER), the first-ever patient ... from PRIMIER , researchers found that the ...
(Date:5/6/2015)... BETHESDA, Md. , May 6, 2015 ... announced that it has finalized agreement with Richard ... through 2021. "We are very pleased to ... and CEO," said Hal Baseman , the Chair ... enjoyed significant success, performance and growth.  Richard has led ...
(Date:5/6/2015)... May 6, 2015 Saint-Gobain has ... manufacture of filtration products, mainly for the life sciences ... filters manufactured in a state-of-the-art plant in ... sold across the globe and will bolster the range ... This acquisition is fully in line with the ...
Breaking Medicine Technology:Integrative Medicine has Positive Impact on Patient Activation, Chronic Pain, Depression 2PDA Extends Richard M. Johnson as President/CEO for Six Additional Years 2Saint-Gobain Acquires ZenPure, a Specialist in Filtration Products 2
... International Foundation for Sonography Education and Research (IFSER) ... the mSCAN (mobile Sonography Clinical Assessment Notebook). Its ... developed by IFSER in 1994, and is the ... sonography. Based on sound research and analysis, the ...
... 27 CutisPharma, Inc. today announced that it has ... Office for its patent (US 7,815,929) regarding a method ... "By its very nature, the process of ... adequate compensation," said Dr. Indu Muni, founder, chairman, and ...
Cached Medicine Technology:IFSER: Introducing the mSCAN 2CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding 2
(Date:5/6/2015)... OH (PRWEB) May 06, 2015 Anitha ... at Hematology Oncology Consultants, Inc. in Columbus, OH. ... and has a special focus in breast cancer, lung cancer, ... and lymphoma as well as benign hematology. , ... and internal medicine by the American Board of Internal Medicine. ...
(Date:5/6/2015)... 2015 Wolters Kluwer , a ... students, announced today that in a survey of nearly ... of the clinical decision support resource improves the quality ... 2014, UpToDate users in more than 170 countries worldwide ... on average. In Germany alone, 95% of all university ...
(Date:5/6/2015)... 2015 Healthcare jobs platform, ... launching in mid-February. The company connects hospitals, home-health, and ... experience in the industry. Likewise, job seekers are able ... Kyle Johnson, CTO, unique traffic to the site is ... "Each new job posting brings targeted, interested candidates to ...
(Date:5/6/2015)... Locally owned, Greek olive oil producer and importer, ... as having one the best Extra Virgin Olive Oils in ... region of Greece and known as Laconiko , received ... Medium Olive Oil, which is defined by the competition as ... 700 producer applicants from 25 different countries applying, Laconiko stood ...
(Date:5/6/2015)... York (PRWEB) May 06, 2015 Dr. Vito ... facial plastic surgeons , recently completed a medical mission trip ... surgery on those affected by microtia and other deformities ... on April 17 and ended on April 26, Dr. Quatela ... patients. Microtia is a congenital deformity where the outside of ...
Breaking Medicine News(10 mins):Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 2Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 3Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Job Seekers Turn to JobMedic to Find Healthcare Positions - JobMedic.com Reaches 1,000 User Milestone 2Health News:Greek Extra Virgin Olive Oil, Laconiko Wins Gold at the NYIOOC and Is Featured in Olive Oil Times as One of Greece's Best EVOO's for 2015 2Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 2Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 3
... insoles can jumpstart the nervous system into action. A new ... people maintain better balance. They proved most effective in elderly ... balance and reduce the number of falls and bone fractures. ... 12 older people. The theory is small vibrations should stimulate ...
... to accelerate death in many people, but previous research has ... ,A new study focuses on depression in elderly people living ... homes. ,The study, involved 250 participants in a community ... the presence of depression and then did so again at ...
... to an increased risk of liver disease. ,Chronic liver ... of death in the United States. Drug use and high-risk ... abuse and hepatitis are both causes of liver disease. The ... risky behavior in adulthood and therefore, increase the risk of ...
... makes its way into the human system when eaten -- and ... ,The compound, called sialic acid, is found on the surfaces of ... one reason why animal-to-human organ and tissue transplants do not work ... ,But researchers at have found it does show up in ...
... elderly women with chronic diseases may be at risk for experiencing ... 60 and 79. The women were asked if they // had ... fallen, and whether they received any medical attention for the falls. ... interview and gave a full drug history report. ,Results ...
... genetically modified rat models of greater predictability and quality. ... to the development of innovative therapeutics for major pathologies ... disorders. ,Rats and mice used in labs ... -- such as a weak immune system, or a ...
Cached Medicine News:Health News:Same molecule found in meat, milk, tumors 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: